ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hepatitis A Inactivated Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-18P18184
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Hepatitis A Inactivated Vaccine Market Research Report 2024
BUY CHAPTERS

Global Hepatitis A Inactivated Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-18P18184
Report
October 2025
Pages:138
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline PLC
Health Pharma
Huakang Pharmaceutical
Limin Pharmaceutical
Xianghe Pharmaceutical

Hepatitis A Inactivated Vaccine Market

The global Hepatitis A Inactivated Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Hepatitis A Inactivated Vaccine is a vaccine used to prevent infection with the hepatitis A virus. It can help protect individuals from infection with the hepatitis A virus and thus prevent related liver diseases.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Hepatitis A Inactivated Vaccine leading manufacturers including Pfizer, Merck, Sanofi, GlaxoSmithKline, Health Pharma, Huakang Pharmaceutical, Limin Pharmaceutical, Xianghe Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Hepatitis A Inactivated Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Hepatitis A Inactivated Vaccine Market Report

Report Metric Details
Report Name Hepatitis A Inactivated Vaccine Market
Segment by Type
  • 25U/0.5ml
  • 50U/1.0ml
Segment by Application
  • Hospital
  • Clinic
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Merck, Sanofi, GlaxoSmithKline, Health Pharma, Huakang Pharmaceutical, Limin Pharmaceutical, Xianghe Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Hepatitis A Inactivated Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Hepatitis A Inactivated Vaccine Market report?

Ans: The main players in the Hepatitis A Inactivated Vaccine Market are Pfizer, Merck, Sanofi, GlaxoSmithKline, Health Pharma, Huakang Pharmaceutical, Limin Pharmaceutical, Xianghe Pharmaceutical

What are the Application segmentation covered in the Hepatitis A Inactivated Vaccine Market report?

Ans: The Applications covered in the Hepatitis A Inactivated Vaccine Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Hepatitis A Inactivated Vaccine Market report?

Ans: The Types covered in the Hepatitis A Inactivated Vaccine Market report are 25U/0.5ml, 50U/1.0ml

1 Study Coverage
1.1 Introduction to Hepatitis A Inactivated Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Hepatitis A Inactivated Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 25U/0.5ml
1.2.3 50U/1.0ml
1.3 Market Segmentation by Application
1.3.1 Global Hepatitis A Inactivated Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hepatitis A Inactivated Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Hepatitis A Inactivated Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Hepatitis A Inactivated Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Hepatitis A Inactivated Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Hepatitis A Inactivated Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Hepatitis A Inactivated Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 25U/0.5ml Market Size by Manufacturers
3.5.2 50U/1.0ml Market Size by Manufacturers
3.6 Global Hepatitis A Inactivated Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Hepatitis A Inactivated Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Hepatitis A Inactivated Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Hepatitis A Inactivated Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Hepatitis A Inactivated Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Hepatitis A Inactivated Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Hepatitis A Inactivated Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Hepatitis A Inactivated Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Hepatitis A Inactivated Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Hepatitis A Inactivated Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Hepatitis A Inactivated Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Hepatitis A Inactivated Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Hepatitis A Inactivated Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Hepatitis A Inactivated Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Hepatitis A Inactivated Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Hepatitis A Inactivated Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Hepatitis A Inactivated Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Hepatitis A Inactivated Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Hepatitis A Inactivated Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Hepatitis A Inactivated Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.1.4 Pfizer Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Pfizer Hepatitis A Inactivated Vaccine Sales by Product in 2024
11.1.6 Pfizer Hepatitis A Inactivated Vaccine Sales by Application in 2024
11.1.7 Pfizer Hepatitis A Inactivated Vaccine Sales by Geographic Area in 2024
11.1.8 Pfizer Hepatitis A Inactivated Vaccine SWOT Analysis
11.1.9 Pfizer Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Business Overview
11.2.3 Merck Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.2.4 Merck Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Merck Hepatitis A Inactivated Vaccine Sales by Product in 2024
11.2.6 Merck Hepatitis A Inactivated Vaccine Sales by Application in 2024
11.2.7 Merck Hepatitis A Inactivated Vaccine Sales by Geographic Area in 2024
11.2.8 Merck Hepatitis A Inactivated Vaccine SWOT Analysis
11.2.9 Merck Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.3.4 Sanofi Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Hepatitis A Inactivated Vaccine Sales by Product in 2024
11.3.6 Sanofi Hepatitis A Inactivated Vaccine Sales by Application in 2024
11.3.7 Sanofi Hepatitis A Inactivated Vaccine Sales by Geographic Area in 2024
11.3.8 Sanofi Hepatitis A Inactivated Vaccine SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Corporation Information
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.4.4 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales by Product in 2024
11.4.6 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales by Application in 2024
11.4.7 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales by Geographic Area in 2024
11.4.8 GlaxoSmithKline Hepatitis A Inactivated Vaccine SWOT Analysis
11.4.9 GlaxoSmithKline Recent Developments
11.5 Health Pharma
11.5.1 Health Pharma Corporation Information
11.5.2 Health Pharma Business Overview
11.5.3 Health Pharma Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.5.4 Health Pharma Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Health Pharma Hepatitis A Inactivated Vaccine Sales by Product in 2024
11.5.6 Health Pharma Hepatitis A Inactivated Vaccine Sales by Application in 2024
11.5.7 Health Pharma Hepatitis A Inactivated Vaccine Sales by Geographic Area in 2024
11.5.8 Health Pharma Hepatitis A Inactivated Vaccine SWOT Analysis
11.5.9 Health Pharma Recent Developments
11.6 Huakang Pharmaceutical
11.6.1 Huakang Pharmaceutical Corporation Information
11.6.2 Huakang Pharmaceutical Business Overview
11.6.3 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.6.4 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Huakang Pharmaceutical Recent Developments
11.7 Limin Pharmaceutical
11.7.1 Limin Pharmaceutical Corporation Information
11.7.2 Limin Pharmaceutical Business Overview
11.7.3 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.7.4 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Limin Pharmaceutical Recent Developments
11.8 Xianghe Pharmaceutical
11.8.1 Xianghe Pharmaceutical Corporation Information
11.8.2 Xianghe Pharmaceutical Business Overview
11.8.3 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Product Models, Descriptions and Specifications
11.8.4 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Xianghe Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Hepatitis A Inactivated Vaccine Industry Chain
12.2 Hepatitis A Inactivated Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Hepatitis A Inactivated Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Hepatitis A Inactivated Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Hepatitis A Inactivated Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Hepatitis A Inactivated Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
GlaxoSmithKline PLC
Health Pharma
Huakang Pharmaceutical
Limin Pharmaceutical
Xianghe Pharmaceutical
List of Tables
 Table 1. Global Hepatitis A Inactivated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Hepatitis A Inactivated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Hepatitis A Inactivated Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Hepatitis A Inactivated Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Hepatitis A Inactivated Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (L)
 Table 7. Global Hepatitis A Inactivated Vaccine Sales by Region (2020-2025) & (L)
 Table 8. Global Hepatitis A Inactivated Vaccine Sales by Region (2026-2031) & (L)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Hepatitis A Inactivated Vaccine Sales by Manufacturers (2020-2025) & (L)
 Table 11. Global Hepatitis A Inactivated Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global Hepatitis A Inactivated Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Hepatitis A Inactivated Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Hepatitis A Inactivated Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis A Inactivated Vaccine as of 2024)
 Table 16. Global Hepatitis A Inactivated Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Hepatitis A Inactivated Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/L)
 Table 18. Key Manufacturers Hepatitis A Inactivated Vaccine Manufacturing Base and Headquarters
 Table 19. Global Hepatitis A Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Hepatitis A Inactivated Vaccine Sales by Type (2020-2025) & (L)
 Table 23. Global Hepatitis A Inactivated Vaccine Sales by Type (2026-2031) & (L)
 Table 24. Global Hepatitis A Inactivated Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Hepatitis A Inactivated Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Hepatitis A Inactivated Vaccine ASP by Type (2020-2031) & (US$/L)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Hepatitis A Inactivated Vaccine Sales by Application (2020-2025) & (L)
 Table 29. Global Hepatitis A Inactivated Vaccine Sales by Application (2026-2031) & (L)
 Table 30. Hepatitis A Inactivated Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Hepatitis A Inactivated Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Hepatitis A Inactivated Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Hepatitis A Inactivated Vaccine ASP by Application (2020-2031) & (US$/L)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Hepatitis A Inactivated Vaccine Growth Accelerators and Market Barriers
 Table 37. North America Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Hepatitis A Inactivated Vaccine Sales (L) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Hepatitis A Inactivated Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Hepatitis A Inactivated Vaccine Sales (L) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Hepatitis A Inactivated Vaccine Sales (L) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Hepatitis A Inactivated Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Hepatitis A Inactivated Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Hepatitis A Inactivated Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Hepatitis A Inactivated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Pfizer Corporation Information
 Table 51. Pfizer Description and Major Businesses
 Table 52. Pfizer Product Models, Descriptions and Specifications
 Table 53. Pfizer Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 54. Pfizer Sales Value Proportion by Product in 2024
 Table 55. Pfizer Sales Value Proportion by Application in 2024
 Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024
 Table 57. Pfizer Hepatitis A Inactivated Vaccine SWOT Analysis
 Table 58. Pfizer Recent Developments
 Table 59. Merck Corporation Information
 Table 60. Merck Description and Major Businesses
 Table 61. Merck Product Models, Descriptions and Specifications
 Table 62. Merck Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 63. Merck Sales Value Proportion by Product in 2024
 Table 64. Merck Sales Value Proportion by Application in 2024
 Table 65. Merck Sales Value Proportion by Geographic Area in 2024
 Table 66. Merck Hepatitis A Inactivated Vaccine SWOT Analysis
 Table 67. Merck Recent Developments
 Table 68. Sanofi Corporation Information
 Table 69. Sanofi Description and Major Businesses
 Table 70. Sanofi Product Models, Descriptions and Specifications
 Table 71. Sanofi Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 72. Sanofi Sales Value Proportion by Product in 2024
 Table 73. Sanofi Sales Value Proportion by Application in 2024
 Table 74. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 75. Sanofi Hepatitis A Inactivated Vaccine SWOT Analysis
 Table 76. Sanofi Recent Developments
 Table 77. GlaxoSmithKline Corporation Information
 Table 78. GlaxoSmithKline Description and Major Businesses
 Table 79. GlaxoSmithKline Product Models, Descriptions and Specifications
 Table 80. GlaxoSmithKline Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 81. GlaxoSmithKline Sales Value Proportion by Product in 2024
 Table 82. GlaxoSmithKline Sales Value Proportion by Application in 2024
 Table 83. GlaxoSmithKline Sales Value Proportion by Geographic Area in 2024
 Table 84. GlaxoSmithKline Hepatitis A Inactivated Vaccine SWOT Analysis
 Table 85. GlaxoSmithKline Recent Developments
 Table 86. Health Pharma Corporation Information
 Table 87. Health Pharma Description and Major Businesses
 Table 88. Health Pharma Product Models, Descriptions and Specifications
 Table 89. Health Pharma Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 90. Health Pharma Sales Value Proportion by Product in 2024
 Table 91. Health Pharma Sales Value Proportion by Application in 2024
 Table 92. Health Pharma Sales Value Proportion by Geographic Area in 2024
 Table 93. Health Pharma Hepatitis A Inactivated Vaccine SWOT Analysis
 Table 94. Health Pharma Recent Developments
 Table 95. Huakang Pharmaceutical Corporation Information
 Table 96. Huakang Pharmaceutical Description and Major Businesses
 Table 97. Huakang Pharmaceutical Product Models, Descriptions and Specifications
 Table 98. Huakang Pharmaceutical Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 99. Huakang Pharmaceutical Recent Developments
 Table 100. Limin Pharmaceutical Corporation Information
 Table 101. Limin Pharmaceutical Description and Major Businesses
 Table 102. Limin Pharmaceutical Product Models, Descriptions and Specifications
 Table 103. Limin Pharmaceutical Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 104. Limin Pharmaceutical Recent Developments
 Table 105. Xianghe Pharmaceutical Corporation Information
 Table 106. Xianghe Pharmaceutical Description and Major Businesses
 Table 107. Xianghe Pharmaceutical Product Models, Descriptions and Specifications
 Table 108. Xianghe Pharmaceutical Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
 Table 109. Xianghe Pharmaceutical Recent Developments
 Table 110. Key Raw Materials Distribution
 Table 111. Raw Materials Key Suppliers
 Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 113. Milestones in Production Technology Evolution
 Table 114. Distributors List
 Table 115. Market Trends and Market Evolution
 Table 116. Market Drivers and Opportunities
 Table 117. Market Challenges, Risks, and Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources


List of Figures
 Figure 1. Hepatitis A Inactivated Vaccine Product Picture
 Figure 2. Global Hepatitis A Inactivated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. 25U/0.5ml Product Picture
 Figure 4. 50U/1.0ml Product Picture
 Figure 5. Global Hepatitis A Inactivated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Clinic
 Figure 8. Others
 Figure 9. Hepatitis A Inactivated Vaccine Report Years Considered
 Figure 10. Global Hepatitis A Inactivated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Hepatitis A Inactivated Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Hepatitis A Inactivated Vaccine Revenue Market Share by Region (2020-2031)
 Figure 14. Global Hepatitis A Inactivated Vaccine Sales (2020-2031) & (L)
 Figure 15. Global Hepatitis A Inactivated Vaccine Sales (CAGR) by Region (2020-2031) (L)
 Figure 16. Global Hepatitis A Inactivated Vaccine Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Hepatitis A Inactivated Vaccine Sales Volume Market Share in 2024
 Figure 18. Global Hepatitis A Inactivated Vaccine Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. 25U/0.5ml Revenue Market Share by Manufacturer in 2024
 Figure 21. 50U/1.0ml Revenue Market Share by Manufacturer in 2024
 Figure 22. Global Hepatitis A Inactivated Vaccine Sales Market Share by Type (2020-2031)
 Figure 23. Global Hepatitis A Inactivated Vaccine Revenue Market Share by Type (2020-2031)
 Figure 24. Global Hepatitis A Inactivated Vaccine Sales Market Share by Application (2020-2031)
 Figure 25. Global Hepatitis A Inactivated Vaccine Revenue Market Share by Application (2020-2031)
 Figure 26. North America Hepatitis A Inactivated Vaccine Sales YoY (2020-2031) & (L)
 Figure 27. North America Hepatitis A Inactivated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Manufacturers Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 29. North America Hepatitis A Inactivated Vaccine Sales Volume (L) by Type (2020- 2031)
 Figure 30. North America Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 31. North America Hepatitis A Inactivated Vaccine Sales Volume (L) by Application (2020-2031)
 Figure 32. North America Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 33. US Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 34. Canada Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Mexico Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 36. Europe Hepatitis A Inactivated Vaccine Sales YoY (2020-2031) & (L)
 Figure 37. Europe Hepatitis A Inactivated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Europe Top 5 Manufacturers Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 39. Europe Hepatitis A Inactivated Vaccine Sales Volume (L) by Type (2020-2031)
 Figure 40. Europe Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Europe Hepatitis A Inactivated Vaccine Sales Volume (L) by Application (2020-2031)
 Figure 42. Europe Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Germany Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 44. France Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. U.K. Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. Italy Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Russia Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Hepatitis A Inactivated Vaccine Sales YoY (2020-2031) & (L)
 Figure 49. Asia-Pacific Hepatitis A Inactivated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Top 8 Manufacturers Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 51. Asia-Pacific Hepatitis A Inactivated Vaccine Sales Volume (L) by Type (2020- 2031)
 Figure 52. Asia-Pacific Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 53. Asia-Pacific Hepatitis A Inactivated Vaccine Sales Volume (L) by Application (2020-2031)
 Figure 54. Asia-Pacific Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Indonesia Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 56. Japan Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. South Korea Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. China Taiwan Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. India Hepatitis A Inactivated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 60. Central and South America Hepatitis A Inactivated Vaccine Sales YoY (2020-2031) & (L)
 Figure 61. Central and South America Hepatitis A Inactivated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 62. Central and South America Top 5 Manufacturers Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 63. Central and South America Hepatitis A Inactivated Vaccine Sales Volume (L) by Type (2021-2031)
 Figure 64. Central and South America Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Central and South America Hepatitis A Inactivated Vaccine Sales Volume (L) by Application (2020-2031)
 Figure 66. Central and South America Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 67. Brazil Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 68. Argentina Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 69. Middle East, and Africa Hepatitis A Inactivated Vaccine Sales YoY (2020-2031) & (L)
 Figure 70. Middle East and Africa Hepatitis A Inactivated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 71. Middle East and Africa Top 5 Manufacturers Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 72. Middle East and Africa Hepatitis A Inactivated Vaccine Sales Volume (L) by Type (2021-2031)
 Figure 73. South America Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 74. Middle East and Africa Hepatitis A Inactivated Vaccine Sales Volume (L) by Application (2020-2031)
 Figure 75. Middle East and Africa Hepatitis A Inactivated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 76. GCC Countries Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 77. Turkey Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. Egypt Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. South Africa Hepatitis A Inactivated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 80. Hepatitis A Inactivated Vaccine Industry Chain Mapping
 Figure 81. Regional Hepatitis A Inactivated Vaccine Manufacturing Base Distribution (%)
 Figure 82. Global Hepatitis A Inactivated Vaccine Production Market Share by Region (2020-2031)
 Figure 83. Hepatitis A Inactivated Vaccine Production Process
 Figure 84. Regional Hepatitis A Inactivated Vaccine Production Cost Structure
 Figure 85. Channels of Distribution (Direct Vs Distribution)
 Figure 86. Bottom-up and Top-down Approaches for This Report
 Figure 87. Data Triangulation
 Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions